Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 11

Publication Record

Connections

Comparison of 60 and 80 mg/m of daunorubicin in induction therapy of acute myeloid leukaemia.
Vaezi M, Bahar B, Mousavi A, Yaghmai M, Kasaeian A, Souri M, Jahani M, Alimoghaddam K, Ghavamzadeh A
(2017) Hematol Oncol 35: 101-105
MeSH Terms: Adolescent, Adult, Antibiotics, Antineoplastic, Chromosome Aberrations, Cytarabine, Daunorubicin, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Febrile Neutropenia, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute, Male, Middle Aged, Mycoses, Neutropenia, Prevalence, Prospective Studies, Remission Induction, Treatment Outcome, Young Adult
Show Abstract · Added September 28, 2015
For finding better method of acute myeloid leukaemia (AML) induction, we designed a prospective clinical trial to find a more effective regimen with least toxicity for induction therapy of AML. Hence, we examined different accepted doses of daunorubicin and their outcomes. Total of 114 patients were included in the study. Fifty-five patients received 60 mg/m of daunorubicin (arm 1) 1 h IV infusion for 3 days, and the remaining 59 received 80 mg/m (arm 2) 1 h IV infusion for 3 days. Continuous infusion of 100 mg/m /day of cytosine arabinozide IV for 24 h for 7 days was given in both groups. Complete remission rate was 77.78% in group 1 and 76.92% in group 2 (p = 0.92). One-year overall survival was 55.85% [standard error (SE) = 8.05%] in arm 1 and 57.94% (SE = 7.32%) in arm 2. Median follow-up time was 11.1 (SE = 1.43) and 10.28 (SE = 1.29) months, respectively. One-year disease-free survival was 64.41% (SE = 7.39%) in arm 1 and 54.86% (SE = 7.53%) in arm 2. Complete remission, overall survival and disease-free survival were statistically the same in both groups (p = 0.92, 0.697, 0.31). Toxicity and safety profile were similar in two groups but need to transfusion was higher in arm 2. Febrile neutropenia, days of antibiotics consumption and invasive fungal infection prevalence did not show any difference. Mean transfused packed cells and platelets rate were higher in the group that received higher dose of daunorubicin. Considering these results, we found that 60 mg/m of daunorubicin would be more rational and as effective with lower toxicity to 80 mg/m in induction therapy of AML patients at least as scheduled in our trial. Copyright © 2015 John Wiley & Sons, Ltd.
Copyright © 2015 John Wiley & Sons, Ltd.
0 Communities
1 Members
0 Resources
24 MeSH Terms
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.
Gamazon ER, Lamba JK, Pounds S, Stark AL, Wheeler HE, Cao X, Im HK, Mitra AK, Rubnitz JE, Ribeiro RC, Raimondi S, Campana D, Crews KR, Wong SS, Welsh M, Hulur I, Gorsic L, Hartford CM, Zhang W, Cox NJ, Dolan ME
(2013) Blood 121: 4366-76
MeSH Terms: Antimetabolites, Antineoplastic, Apoptosis, Cytarabine, Drug Resistance, Neoplasm, Gene Expression Regulation, Leukemic, Genome-Wide Association Study, Genotype, Humans, Leukemia, Myeloid, Acute, Phenotype, Polymorphism, Single Nucleotide, Treatment Outcome
Show Abstract · Added February 22, 2016
A whole-genome approach was used to investigate the genetic determinants of cytarabine-induced cytotoxicity. We performed a meta-analysis of genome-wide association studies involving 523 lymphoblastoid cell lines (LCLs) from individuals of European, African, Asian, and African American ancestry. Several of the highest-ranked single-nucleotide polymorphisms (SNPs) were within the mutated in colorectal cancers (MCC) gene. MCC expression was induced by cytarabine treatment from 1.7- to 26.6-fold in LCLs. A total of 33 SNPs ranked at the top of the meta-analysis (P < 10(-5)) were successfully tested in a clinical trial of patients randomized to receive low-dose or high-dose cytarabine plus daunorubicin and etoposide; of these, 18 showed association (P < .05) with either cytarabine 50% inhibitory concentration in leukemia cells or clinical response parameters (minimal residual disease, overall survival (OS), and treatment-related mortality). This count (n = 18) was significantly greater than expected by chance (P = .016). For rs1203633, LCLs with AA genotype were more sensitive to cytarabine-induced cytotoxicity (P = 1.31 × 10(-6)) and AA (vs GA or GG) genotype was associated with poorer OS (P = .015), likely as a result of greater treatment-related mortality (P = .0037) in patients with acute myeloid leukemia (AML). This multicenter AML02 study trial was registered at www.clinicaltrials.gov as #NCT00136084.
0 Communities
2 Members
0 Resources
12 MeSH Terms
Thr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer.
Nifoussi SK, Vrana JA, Domina AM, De Biasio A, Gui J, Gregory MA, Hann SR, Craig RW
(2012) PLoS One 7: e47060
MeSH Terms: Animals, Antineoplastic Agents, Apoptosis, Blotting, Western, CHO Cells, Cell Line, Tumor, Cisplatin, Cricetinae, Cytarabine, Drug Resistance, Neoplasm, Etoposide, Flow Cytometry, Glycogen Synthase Kinase 3, Humans, Myeloid Cell Leukemia Sequence 1 Protein, Phosphorylation, Protein Stability, Proto-Oncogene Proteins c-bcl-2, Threonine, Vinblastine
Show Abstract · Added March 20, 2014
The antiapoptotic Bcl-2 family member Mcl-1 is a PEST protein (containing sequences enriched in proline, glutamic acid, serine, and threonine) and is subject to rapid degradation via multiple pathways. Impaired degradation leading to the maintenance of Mcl-1 expression is an important determinant of drug resistance in cancer. Phosphorylation at Thr 163 in the PEST region, stimulated by 12-O-tetradecanoylphorbol acetic acid (TPA)-induced activation of extracellular signal-regulated kinase (ERK), is associated with Mcl-1 stabilization in BL41-3 Burkitt lymphoma cells. This contrasts with the observation that Thr 163 phosphorylation in normal fibroblasts primes glycogen synthase kinase (GSK3)-induced phosphorylation at Ser 159, producing a phosphodegron that targets Mcl-1 for degradation. In the present follow-up studies in BL41-3 cells, Mcl-1 degradation was found to be independent of the GSK3-mediated pathway, providing a parallel to emerging findings showing that Mcl-1 degradation through this pathway is lost in many different types of cancer. Findings in Mcl-1-transfected CHO cells corroborated those in BL41-3 cells in that the GSK3-targeted phosphodegron did not play a major role in Mcl-1 degradation, and a phosphomimetic T163E mutation resulted in marked Mcl-1 stabilization. TPA-treated BL41-3 cells, in addition to exhibiting Thr 163 phosphorylation and Mcl-1 stabilization, exhibited an ∼10-fold increase in resistance to multiple chemotherapeutic agents, including Ara-C, etoposide, vinblastine, or cisplatin. In these cancer cells in which Mcl-1 degradation is not dependent on the GSK3/phosphodegron-targeted pathway, ERK activation and Thr 163 phosphorylation are associated with pronounced Mcl-1 stabilization and drug resistance - effects that can be suppressed by inhibition of ERK activation.
0 Communities
1 Members
0 Resources
20 MeSH Terms
Persistent sonic hedgehog signaling in adult brain determines neural stem cell positional identity.
Ihrie RA, Shah JK, Harwell CC, Levine JH, Guinto CD, Lezameta M, Kriegstein AR, Alvarez-Buylla A
(2011) Neuron 71: 250-62
MeSH Terms: Age Factors, Animals, Calbindins, Cell Movement, Cerebral Ventricles, Choline O-Acetyltransferase, Cytarabine, Estrogen Antagonists, Gene Expression Regulation, Hedgehog Proteins, Immunosuppressive Agents, Kruppel-Like Transcription Factors, Luminescent Proteins, Mice, Mice, Transgenic, Neural Stem Cells, Neurons, Olfactory Bulb, RNA, Messenger, Receptors, G-Protein-Coupled, S100 Calcium Binding Protein G, Signal Transduction, Smoothened Receptor, Stilbamidines, Tamoxifen, Time Factors, Tyrosine 3-Monooxygenase, Zinc Finger Protein GLI1
Show Abstract · Added August 21, 2012
Neural stem cells (NSCs) persist in the subventricular zone (SVZ) of the adult brain. Location within this germinal region determines the type of neuronal progeny NSCs generate, but the mechanism of adult NSC positional specification remains unknown. We show that sonic hedgehog (Shh) signaling, resulting in high gli1 levels, occurs in the ventral SVZ and is associated with the genesis of specific neuronal progeny. Shh is selectively produced by a small group of ventral forebrain neurons. Ablation of Shh decreases production of ventrally derived neuron types, while ectopic activation of this pathway in dorsal NSCs respecifies their progeny to deep granule interneurons and calbindin-positive periglomerular cells. These results show that Shh is necessary and sufficient for the specification of adult ventral NSCs.
Copyright © 2011 Elsevier Inc. All rights reserved.
1 Communities
1 Members
0 Resources
28 MeSH Terms
Working memory in survivors of childhood acute lymphocytic leukemia: functional neuroimaging analyses.
Robinson KE, Livesay KL, Campbell LK, Scaduto M, Cannistraci CJ, Anderson AW, Whitlock JA, Compas BE
(2010) Pediatr Blood Cancer 54: 585-90
MeSH Terms: Adolescent, Age of Onset, Antineoplastic Agents, Brain, Brain Mapping, Child, Child, Preschool, Cytarabine, Female, Humans, Intelligence Tests, Magnetic Resonance Imaging, Male, Memory Disorders, Memory, Short-Term, Methotrexate, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Survivors
Show Abstract · Added March 7, 2014
BACKGROUND - Research on the physical and psychological late effects of treatment of childhood cancer has led to the identification of significant long-term neurocognitive deficits experienced by some survivors, particularly in the areas of memory and executive functioning. Despite indications of deficits based on cognitive assessment, the identification of specific mechanisms of neurocognitive deficits using neuroimaging techniques has yet to be adequately considered.
PROCEDURE - This study used functional neuroimaging techniques to examine working memory and executive functioning deficits of survivors of childhood acute lymphocytic leukemia (ALL), as compared to age- and gender-matched healthy controls.
RESULTS - There was a trend for ALL survivors to perform more poorly on a working memory task in terms of overall accuracy. Additionally, survivors displayed significantly greater activation in areas underlying working memory (dorsolateral and ventrolateral prefrontal cortex) and error monitoring (dorsal and ventral anterior cingulate cortex).
CONCLUSIONS - These results support the theory of compensatory activation in necessary brain regions in order to complete tasks in pediatric ALL survivors, similar to that observed in multiple sclerosis patients. Concurrent examination of testing and brain imaging enables the connection of behavioral observations with underlying neurological characteristics of deficits in survivors and may help provide insight into mechanisms through which deficits appear.
0 Communities
1 Members
0 Resources
18 MeSH Terms
The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines.
Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, Matherly LH, Taub JW
(2004) Cancer Res 64: 728-35
MeSH Terms: Base Sequence, Cell Death, Cell Line, Tumor, Cells, Cultured, Cytarabine, Cytosine Deaminase, DNA Primers, DNA-Binding Proteins, Down Syndrome, Erythroid-Specific DNA-Binding Factors, Exons, GATA1 Transcription Factor, Humans, Introns, Leukemia, Molecular Sequence Data, Reverse Transcriptase Polymerase Chain Reaction, Transcription Factors, Transcription, Genetic
Show Abstract · Added March 5, 2014
Myeloblasts from Down syndrome (DS) children with acute myeloid leukemia (AML) are significantly more sensitive in vitro to 1-beta-D-arabinofuranosylcytosine (ara-C) and generate higher 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP) than non-DS AML myeloblasts. Semiquantitative reverse transcription-PCR analyses demonstrated that transcripts for cytidine deaminase (CDA) were 2.7-fold lower in DS than for non-DS myeloblasts. In contrast, transcripts of cystathionine-beta-synthase and deoxycytidine kinase were a median 12.5- and 2.6-fold higher in DS compared with non-DS myeloblasts. The ratio of deoxycytidine kinase/CDA transcripts significantly correlated with ara-C sensitivities and ara-CTP generation. In clinically relevant AML cell line models, high cystathionine-beta-synthase transcripts in DS CMK cells were accompanied by 10-fold greater ara-C sensitivity and 2.4-fold higher levels of ara-CTP compared with non-DS CMS cells. Overexpression of CDA in non-DS THP-1 cells was associated with a 100-fold decreased ara-C sensitivity and 40-fold decreased ara-CTP generation. THP-1 cells secreted CDA into the incubation media and converted extracellular ara-C completely to 1-beta-D-arabinofuranosyluracil within 30 min. Rapid amplification of 5'-cDNA ends (5'-RACE) and reverse transcription-PCR assays identified short- (sf) and long-form (lf) CDA transcripts in THP-1 cells with different 5' untranslated regions and translational start sites; however, only the latter resulted in the active CDA. Although 5' flanking sequences for both CDA transcripts exhibited promoter activity in reporter gene assays, activity for the CDAlf was low. The presence of several GATA1 binding sites in the CDAsf promoter and the uniform detection of GATA1 mutations in DS megakaryocytic leukemia suggested the potential role of GATA1 in regulating CDA transcription and the CDAsf promoter acting as an enhancer. Transfection of GATA1 into Drosophila Mel-2 cells stimulated the CDAlf promoter in a dose-dependent fashion. Additional identification of the mechanisms of differential expression of genes encoding enzymes involved in ara-C metabolism between DS and non-DS myeloblasts may lead to improvements in AML therapy.
0 Communities
1 Members
0 Resources
19 MeSH Terms
Age and cytogenetics as predictors of event free survival in patients with acute non-lymphocytic leukemia receiving high dose cytosine arabinoside and daunorubicin as consolidation chemotherapy.
Stein RS, Wolff SN, Greer JP, Flexner JM, Goodman S, Jagasia M, Brandt SJ, Morgan DS, Arrowsmith E, McCurley TL
(2001) Leuk Lymphoma 42: 913-22
MeSH Terms: Actuarial Analysis, Adult, Age Factors, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Cytogenetic Analysis, Daunorubicin, Disease-Free Survival, Female, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors
Show Abstract · Added March 5, 2014
Between 1991 and 1999, 67 patients with acute non-lymphocytic leukemia (ANLL) in complete remission received high dose cytarabine (HiDAC) 3 gm/m2 q12h x 12 doses followed by daunorubicin 45 mg/m2/day x 3 days as consolidation therapy. Five year actuarial event free survival (EFS) was 34% +/- 6%. Age was significantly associated with EFS. EFS was 60% +/- 15% in patients age 20 to 29, 48% +/- 16% in patients age 30 to 39, 23% +/- 10% in patients age 40 to 49, 31% +/- 11% in patients age 50 to 59, and 0% in patients age > or = 60. Contrary to other reports which have used different HiDAC regimens, we found no relationship between cytogenetics and EFS. Cytogenetics were defined as favorable risk: t(8;21), inv (16), and del (16); neutral risk: normal or t(15;17); and unfavorable risk: any abnormality not included in favorable risk or neutral risk. EFS was 29% +/- 17% in patients with favorable cytogenetics, 37% +/- 14% in patients with neutral cytogenetics, and 31% +/- 12% in patients with unfavorable cytogenetics. These differences were not statistically significant. Because of the successful use of allogeneic transplantation at relapse in patients with matched related donors, five year actuarial survival (S) in this series was 40% +/- 6%. Five year actuarial survival was 57% +/- 9% for patients age < or = 44 and 25% +/- 8% for patients age > or = 45. This difference is statistically significant, p < .025. Clinicians should be cautious about making clinical decisions regarding consolidation therapy of ANLL on the basis of the presence or absence of cytogenetic abnormalities as the importance of cytogenetics may depend on the specific therapy which is employed.
0 Communities
2 Members
0 Resources
16 MeSH Terms
Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes.
Cline SD, Osheroff N
(1999) J Biol Chem 274: 29740-3
MeSH Terms: Base Sequence, Cytarabine, DNA, DNA Primers, Humans, Hydrolysis, Topoisomerase II Inhibitors
Show Abstract · Added March 5, 2014
Cytosine arabinoside (araC) is an important drug used for the treatment of human leukemias. In order to exert its cytotoxic effects, araC must be incorporated into chromosomal DNA. Although specific DNA lesions that involve base loss or modification stimulate nucleic acid cleavage mediated by type II topoisomerases, the effects of deoxyribose sugar ring modification on enzyme activity have not been examined. Therefore, the effects of incorporated araC residues on the DNA cleavage/religation equilibrium of human topoisomerase IIalpha and beta were characterized. AraC lesions were position-specific topoisomerase II poisons and stimulated DNA scission mediated by both human type II enzymes. However, the positional specificity of araC residues differed from that previously reported for other cleavage-enhancing DNA lesions. Finally, additive or synergistic increases in DNA cleavage were observed in the presence of araC lesions and etoposide. These findings broaden the range of DNA lesions known to alter topoisomerase II function and raise the possibility that this enzyme may mediate some of the cellular effects of araC.
0 Communities
1 Members
0 Resources
7 MeSH Terms
Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction.
Ajani JA, Roth JA, Putnam JB, Walsh G, Lynch PM, Roubein LD, Ryan MB, Natrajan G, Gould P
(1995) Eur J Cancer 31A: 665-70
MeSH Terms: Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Combined Modality Therapy, Cytarabine, Drug Administration Schedule, Esophageal Neoplasms, Female, Fluorouracil, Humans, Male, Middle Aged, Premedication, Stomach Neoplasms, Survival Rate, Ultrasonography
Show Abstract · Added March 27, 2014
The purpose of this study was to examine the feasibility of administering all chemotherapy pre-operatively to patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. 32 patients with potentially resectable adenocarcinoma of the oesophagus or gastrooesophageal junction were studied in a stepwise fashion in which combination chemotherapy with cisplatin, high-dose arabinoside and 5-fluorouracil was administered. In the first part, 15 patients were to receive three chemotherapy courses pre-operatively and two chemotherapy courses postoperatively. In the second part, the next 15 patients were to receive all five chemotherapy courses pre-operatively, provided there was an objective response after three courses. Endoscopic ultrasonography was also performed, when feasible, prior to chemotherapy and surgery, and in some patients sequentially between chemotherapy courses. All of the 14 assessable patients in the first group tolerated all three courses of pre-operative chemotherapy, and 86% of patients in this group completed all protocol chemotherapy. In the second group, 9 of 18 (50%) assessable patients tolerated all five courses of preoperative chemotherapy, and 100% of patients in this group received all protocol chemotherapy. The median number of chemotherapy courses for the entire group (32 patients) was five (range one to five). Forty-one per cent (13/32) of patients had a major response to chemotherapy. Sixty-nine per cent (or 76% of 29 patients taken to surgery) had a curative resection. One patient had a pathological complete response. The median survival time of 32 patients was 17 months (range 2-36+ months). 14 patients (37%) remain alive at a median follow-up time of 26+ months. There was a correlation between endoscopic ultrasonographic tumour and nodal stage and pathological tumour and nodal stages in 16 patients. The tumour stage correlation was higher (75%) than the nodal stage correlation (62%). Our data suggest that it is feasible to administer five courses of cisplatin-based chemotherapy to patients with potentially resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. More effective chemotherapy regimens that might result in higher pathological complete response rates and acceptable toxic effects are needed.
0 Communities
1 Members
0 Resources
18 MeSH Terms
Progressive multifocal leukoencephalopathy.
Minnick A, Oleson AJ
(1982) J Neurosurg Nurs 14: 82-4
MeSH Terms: Anti-Bacterial Agents, Cytarabine, Humans, Leukoencephalopathy, Progressive Multifocal, Patient Education as Topic, Virus Diseases
Added January 20, 2015
0 Communities
1 Members
0 Resources
6 MeSH Terms